• 대한골관절종양학회지
• /
• 제14권2호
• /
• pp.79-85
• /
• 2008

연조직종양의 분류는 종양학에서 영상의학과의사와 임상을 담당하는 정형외과의사, 종양학자 그리고 병리학자의 진단과 예후의 재현을 용이하게 하는 필수적인 지침이다. 연조직종양의 이해는 과거 10년 동안에 걸쳐 주요 변화와 더불어 진보가 있었고, 이를 바탕으로 연조직종양의 새로운 분류가 WHO에 의해 2002년에 이루어졌다. 이 개정은 이전에 발표된 분류와 많은 부분에서 다른 내용의 접근을 하였고, 이 작업에는 유전학과 분자생물학 그리고 임상분야의 전문가들이 참여하였다. 여기에서는 과거에 알고 있었거나 특성이 알려진 종양을 포함하여 새로운 큰 변화나 작은 변화가 일어난 부분에 대해서 정리를 하였다. 이러한 내용의 연조직종양의 새로운 WHO 분류를 혈관종, 연골-골종 그리고 불확실한분화종을 중심으로, 큰 변화와 작은 변화로 나누어서 설명하고 새롭게 소개되는 병명을 정리하였다. 이 새로운 WHO의 연조직 종양의 분류를 이해하여, 종양의 진단과 예후의 재현을 용이하게 하는 필수적인 지침으로 사용할 수 있을 것으로 생각된다.

• Journal of Digestive Cancer Research
• /
• 제9권2호
• /
• pp.57-59
• /
• 2021

Carcinoid tumor is called as neuroendocrine tumor and is classified into neuroendocrine tumor Grade 1, neuroendocrine tumor Grade 2, and neuroendocrine carcinoma based on the differentiation of tumors. Recently, the incidence of rectal carcinoid tumor has been increasing probably due to the increased interest on screening colonoscopy and the advancement of endoscopic imaging technology. As the rectal carcinoid shows a wide range of clinical characteristics such as metastasis and long-term prognosis depending on the size and histologic features, it is a challenge to give a consistent diagnostic code in patients with the rectal carcinoid. If the rectal carcinoid tumor is less than 1 cm in size, it can be given as the code of definite malignancy or the code of uncertain malignant potential according to International Classification of Diseases for Oncology (ICD-O) by World Health Organization (WHO). Because patients get different amount of benefit from the insurance company based on different diagnostic codes, this inconsistent coding system has caused a significant confusion in the clinical practice. In 2019, WHO updated ICD-O and Statistics Korea subsequently changed Korean Standard Classification of Diseases (KCD) including the code of rectal carcinoid tumors. This review will summarize what has been changed in recent ICD-O and KCD system regarding the rectal carcinoid tumor and surmise its clinical implication.

• BMB Reports
• /
• 제56권4호
• /
• pp.258-264
• /
• 2023

As a high-grade soft-tissue sarcoma (STS), undifferentiated pleomorphic sarcoma (UPS) is highly recurrent and malignant. UPS is categorized as a tumor of uncertain differentiation and has few options for treatment due to its lack of targetable genetic alterations. There are also few cell lines that provide a representative model for UPS, leading to a dearth of experimental research. Here, we established and characterized new cell lines derived from two recurrent UPS tissues. Cells were obtained from UPS tissues by mincing, followed by extraction or dissociation using enzymes and culture in a standard culture environment. Cells were maintained for several months without artificial treatment, and some cell clones were found to be tumorigenic in an immunodeficient mouse model. Interestingly, some cells formed tumors in vivo when injected after aggregation in a non-adherent culture system for 24 h. The tissues from in vivo study and tissues from patients shared common histological characteristics. Pathways related to the cell cycle, such as DNA replication, were enriched in both cell clones. Pathways related to cell-cell adhesion and cell-cell signaling were also enriched, suggesting a role of the mesenchymal-to-epithelial transition for tumorigenicity in vivo. These new UPS cell lines may facilitate research to identify therapeutic strategies for UPS.